APLS
Price
$17.82
Change
+$0.01 (+0.06%)
Updated
May 9, 12:18 PM (EDT)
Capitalization
2.26B
94 days until earnings call
CRBP
Price
$6.39
Change
+$0.26 (+4.24%)
Updated
May 9, 12:41 PM (EDT)
Capitalization
75.01M
Ad is loading...

APLS vs CRBP

Header iconAPLS vs CRBP Comparison
Open Charts APLS vs CRBPBanner chart's image
Apellis Pharmaceuticals
Price$17.82
Change+$0.01 (+0.06%)
Volume$300
Capitalization2.26B
Corbus Pharmaceuticals Holdings
Price$6.39
Change+$0.26 (+4.24%)
Volume$100
Capitalization75.01M
APLS vs CRBP Comparison Chart
Loading...
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APLS vs. CRBP commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLS is a Buy and CRBP is a Hold.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (APLS: $17.81 vs. CRBP: $6.13)
Brand notoriety: APLS and CRBP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLS: 120% vs. CRBP: 0%
Market capitalization -- APLS: $2.26B vs. CRBP: $75.01M
APLS [@Biotechnology] is valued at $2.26B. CRBP’s [@Biotechnology] market capitalization is $75.01M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLS’s FA Score shows that 0 FA rating(s) are green whileCRBP’s FA Score has 0 green FA rating(s).

  • APLS’s FA Score: 0 green, 5 red.
  • CRBP’s FA Score: 0 green, 5 red.
According to our system of comparison, CRBP is a better buy in the long-term than APLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLS’s TA Score shows that 4 TA indicator(s) are bullish while CRBP’s TA Score has 5 bullish TA indicator(s).

  • APLS’s TA Score: 4 bullish, 4 bearish.
  • CRBP’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both APLS and CRBP are a good buy in the short-term.

Price Growth

APLS (@Biotechnology) experienced а -11.30% price change this week, while CRBP (@Biotechnology) price change was -18.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.07%. For the same industry, the average monthly price growth was +11.11%, and the average quarterly price growth was -13.36%.

Reported Earning Dates

APLS is expected to report earnings on Aug 11, 2025.

CRBP is expected to report earnings on Mar 11, 2025.

Industries' Descriptions

@Biotechnology (-5.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
APLS($2.26B) has a higher market cap than CRBP($75M). APLS YTD gains are higher at: -44.187 vs. CRBP (-48.051). CRBP has higher annual earnings (EBITDA): -37.75M vs. APLS (-154.53M). APLS has more cash in the bank: 411M vs. CRBP (149M). CRBP has less debt than APLS: CRBP (3.24M) vs APLS (470M). APLS has higher revenues than CRBP: APLS (781M) vs CRBP (0).
APLSCRBPAPLS / CRBP
Capitalization2.26B75M3,015%
EBITDA-154.53M-37.75M409%
Gain YTD-44.187-48.05192%
P/E RatioN/AN/A-
Revenue781M0-
Total Cash411M149M276%
Total Debt470M3.24M14,511%
FUNDAMENTALS RATINGS
APLS vs CRBP: Fundamental Ratings
APLS
CRBP
OUTLOOK RATING
1..100
424
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
54
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9594
PRICE GROWTH RATING
1..100
9065
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRBP's Valuation (54) in the Biotechnology industry is in the same range as APLS (69) in the Medical Distributors industry. This means that CRBP’s stock grew similarly to APLS’s over the last 12 months.

CRBP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as APLS (100) in the Medical Distributors industry. This means that CRBP’s stock grew similarly to APLS’s over the last 12 months.

CRBP's SMR Rating (94) in the Biotechnology industry is in the same range as APLS (95) in the Medical Distributors industry. This means that CRBP’s stock grew similarly to APLS’s over the last 12 months.

CRBP's Price Growth Rating (65) in the Biotechnology industry is in the same range as APLS (90) in the Medical Distributors industry. This means that CRBP’s stock grew similarly to APLS’s over the last 12 months.

CRBP's P/E Growth Rating (100) in the Biotechnology industry is in the same range as APLS (100) in the Medical Distributors industry. This means that CRBP’s stock grew similarly to APLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APLSCRBP
RSI
ODDS (%)
Bullish Trend 1 day ago
67%
Bearish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 8 days ago
81%
Bullish Trend 8 days ago
80%
Declines
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
82%
Aroon
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
79%
View a ticker or compare two or three
Ad is loading...
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SICWX67.43N/A
N/A
Touchstone Large Cap Focused Y
VEIPX41.96N/A
N/A
Vanguard Equity-Income Inv
BRUFX510.78N/A
N/A
Bruce
ICMBX12.57N/A
N/A
Intrepid Capital Investor
ERIFX11.57N/A
N/A
Eaton Vance Balanced R

APLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with ROIV. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
-1.00%
ROIV - APLS
46%
Loosely correlated
-1.25%
BEAM - APLS
42%
Loosely correlated
+6.32%
NTLA - APLS
42%
Loosely correlated
+13.58%
DNLI - APLS
41%
Loosely correlated
+0.77%
RCKT - APLS
40%
Loosely correlated
+11.57%
More

CRBP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRBP has been loosely correlated with SKYE. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CRBP jumps, then SKYE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRBP
1D Price
Change %
CRBP100%
N/A
SKYE - CRBP
49%
Loosely correlated
-1.65%
FBIO - CRBP
38%
Loosely correlated
-1.74%
STOK - CRBP
37%
Loosely correlated
+4.50%
APLS - CRBP
35%
Loosely correlated
-1.00%
PMCB - CRBP
32%
Poorly correlated
+4.11%
More